新年开新篇，奋进启新程。 在"十五五"开局之年，全国各地涌动实干热潮，各行各业抢抓开局、聚力攻坚，从科技创新研发到 企业生产一线，从项目建设现场到消费市场前沿，发展的活力持续迸发，为2026年经济发展筑好基、开 好局。 在服务新产业中发展新产业 浙江杭州，在算力与新材料赛道，传化集团旗下新安股份交出了硅基液冷领域技术与商用双突破的 新年答卷。 "我们依托60年有机硅材料研发与工程化经验，成功开发出具备高绝缘性、极低挥发性、优异热稳 定性及环境友好特性的硅基冷却液，完美适配浸没式液冷的严苛要求。"新安股份硅基新材料研究院院 长刘继指着浸没在透明冷却液中的服务器，详细讲解硅基液冷解决方案的细节。 针对数据中心、储能安全、超快充电等不同高热场景，新安股份已形成系列化产品矩阵，覆盖从材 料到系统的全链条，首个硅基浸没液冷商用项目在杭州稳定运行，其在新技术、新场景、新产业领域的 探索步伐还在继续。 眼下，液冷成为算力刚需，硅基材料凭借性能、成本与环保三重优势，成为液冷产业化的核心支 撑，市场空间加速打开，2026年有望迎来液冷产业化放量的关键节点。 "应用场景越多样、需求越细分，发展潜力就越大。"刘继充满信心地说，"今 ...

Core Viewpoint - Merck's initiation of global Phase I clinical trials for the small molecule oral GLP-1 candidate MK-4082 represents a strategic move to regain market share in metabolic diseases post-DPP-4 era, focusing on broader health issues beyond glucose control [4][7]. Group 1: Merck's Strategy and Market Position - The collaboration between Merck and domestic company Haosen Pharmaceutical involves a clear financial structure, with Haosen receiving an upfront payment of $112 million and potential milestone payments up to $1.9 billion, along with revenue-sharing arrangements [6]. - Merck's choice to pursue small molecules instead of injectable large molecules is driven by the competitive landscape, where established players have set high clinical data standards and built extensive supply chains [7]. - The oral GLP-1 approach is seen as more scalable and suitable for large-scale commercialization, aligning with Merck's capabilities in managing broad indications [7]. Group 2: Industry Trends and Competitor Strategies - Major competitors like Novo Nordisk and Eli Lilly are fully engaged in the market with a comprehensive approach, including injectables and oral formulations, while focusing on supply capabilities and pricing strategies [8]. - Other companies, such as Roche and AstraZeneca, are diversifying their strategies, with Roche acquiring assets to enhance its portfolio and AstraZeneca pursuing both small molecule oral GLP-1 and multi-target approaches [9][10]. - Pfizer's strategy involves acquiring new generation long-acting assets and small molecule projects to mitigate risks associated with single project failures [9]. Group 3: Implications for Chinese Pharmaceutical Companies - The significance of MK-4082 extends to Chinese innovative drug companies, as the focus shifts from single-target me-too drugs to those with platform value, emphasizing small molecules, dual or multi-targets, and ultra-long-acting formulations [11]. - The market will closely monitor MK-4082's Phase I results for pharmacokinetics and tolerability, as well as Merck's potential to expand its asset portfolio with complementary mechanisms [11].

Group 1: Pharmaceutical and Biotechnology Industry - The pharmaceutical and biotechnology sector saw an overall increase of 0.14% last week, outperforming the CSI 300 index by 1.47 percentage points, with a current PE valuation of 29.43 times, which is at a historical mid-low level, representing a 120% premium over the CSI 300 [6][7] - Notable individual stock performances included Guangshengtang, which surged by 29.83%, followed by Haixiang Pharmaceutical at 18.64%, and Meidisi at 18.04% [6] - A significant collaboration was announced between Saint Gene and Gene Tech, involving a global R&D cooperation and licensing agreement for an RNAi therapy, with an upfront payment of $200 million and potential milestone payments totaling $1.5 billion [7][8] - The investment recommendation focuses on three main lines: biotech firms with core delivery technology and international collaboration potential, industry leaders in chronic disease areas with advanced pipelines, and key companies in the small nucleic acid supply chain benefiting from global commercialization [8] Group 2: Machinery and Equipment Industry - In January 2026, excavator sales reached 18,708 units, a year-on-year increase of 49.5%, with domestic sales up 61.4% and exports up 40.5% [11][12] - Loader sales also saw significant growth, with a total of 11,759 units sold in January, reflecting a 48.5% increase year-on-year, driven by major domestic projects [13] - The demand for excavators is expected to continue recovering due to upcoming large-scale projects in various sectors, including mining and water conservancy [12][14] - Companies like LiuGong are projected to see steady profit growth, with a forecasted net profit of 1.526 to 1.659 billion yuan for 2025, marking a 15-25% increase year-on-year [13] Group 3: Electronics Industry - The electronics sector is experiencing a recovery, with significant capital expenditure increases from major CSP manufacturers, expected to reach $670 billion in 2026, a 60% year-on-year increase [16][17] - The global semiconductor industry is projected to achieve record sales of $791.7 billion in 2025, with a 25.6% year-on-year growth, driven by demand from AI and IoT technologies [18] - Price increases are spreading from memory chips to power, analog, and MCU chips, indicating a comprehensive price surge in the semiconductor market [18] - Investment recommendations include focusing on companies benefiting from strong domestic and international demand in the AIOT sector, as well as those involved in semiconductor equipment and materials [21]

Core Insights - The Chinese quick-freezing machine industry is at a critical juncture of opportunities and challenges, characterized by strong demand growth and accelerated technological upgrades. The market size is projected to reach approximately 3.946 billion yuan in 2024, representing a year-on-year growth of 10.35% [1][8]. Industry Overview - Quick-freezing machines, also known as freezing equipment, are industrial refrigeration devices primarily used for rapid freezing of food products. They function by using refrigeration systems and air circulation to lower the center temperature of items to below -18°C within 30 minutes, minimizing nutrient loss [2][4]. - The industry includes various types of quick-freezing machines, such as tunnel freezers, spiral freezers, fluidized freezers, and liquid nitrogen freezers [3]. Market Size - The growth in the quick-freezing machine market is driven by multiple demand engines, including the explosive growth of the prepared food industry, which increases the demand for high-end equipment like liquid nitrogen and spiral freezers. Additionally, the biopharmaceutical sector's requirements for ultra-low temperature storage and frost-free technology, along with the expansion of cold chain logistics, are contributing to the demand [1][7][8]. Industry Chain - The upstream of the quick-freezing machine industry includes raw materials and components such as steel, stainless steel, compressors, evaporators, fans, sensors, control systems, and environmentally friendly refrigerants. The midstream involves the manufacturing of quick-freezing machines, while the downstream applications span food processing, biopharmaceuticals, chemicals, and electronics [4]. Key Companies - The competitive landscape of the quick-freezing machine industry is characterized by leading companies such as Ice Wheel Environment, which offers a full-service capability from core compressors to large-scale spiral and tunnel freezing production lines. Ice Mountain Cold is also a key player with advanced technology in industrial refrigeration and commercial cold chain sectors [8][9][11]. Industry Development Trends 1. **Technological Innovation**: The focus is shifting from merely preserving food to enhancing its quality through advanced freezing technologies, such as the "cloud freezing" technology that minimizes cell damage and juice loss [13]. 2. **Customized Solutions**: The rapid growth of the prepared food industry is driving the need for diverse and refined equipment solutions, requiring quick-freezing machines to adapt to various food types and freezing requirements [14]. 3. **Smart and Green Development**: The industry's future will revolve around smart technologies and sustainability, integrating IoT, AI, and energy-efficient practices to enhance operational efficiency and reduce environmental impact [15].

Core Viewpoint - Haier Group is accelerating its capital expansion with plans for IPOs of its subsidiaries, including the industrial internet platform Kaos and Haier New Energy, potentially increasing its total market value to over 350 billion yuan [1][5]. Group 1: IPO Developments - Kaos submitted its IPO application to the Hong Kong Stock Exchange on January 30, 2026, becoming a highly anticipated industrial technology IPO project [1]. - Haier New Energy has completed its listing counseling and is preparing for its IPO after a successful financing round exceeding 1 billion yuan [3][4]. Group 2: Business Performance - Kaos has over 9,500 paying customers and ranks first in China's market for platform-based industrial data intelligence solutions, with a revenue of 4.421 billion yuan for the first nine months of 2025, a 21.62% increase year-on-year [2]. - The revenue from Kaos's data intelligence solutions reached approximately 1.149 billion yuan in 2024, growing by about 25.9%, and 1.28 billion yuan in the first nine months of 2025, a 59.6% increase [2]. Group 3: Global Expansion - Kaos's international revenue reached approximately 709 million yuan in 2024, with solutions deployed in over 20 countries and serving more than 50 overseas enterprises [3]. - The company has empowered 17 lighthouse factories globally, establishing the largest and most diverse "lighthouse cluster" [3]. Group 4: Strategic Vision - Haier Group aims to create a sustainable ecosystem through its three main sectors: smart home, digital economy, and health, focusing on continuous innovation and adaptability [6]. - The expansion of the "Haier system" is not merely a top-down strategy but a result of internal organizational reforms to enhance creativity and value generation [6].

Core Findings - The research indicates a significant positive correlation between good ESG practices and corporate brand value, with the environmental (E) and governance (G) dimensions having a more pronounced positive impact [2][9] - Under the "dual carbon" goals, companies' green production and energy-saving performance are more likely to gain international recognition, while governance structure optimization enhances market trust [2][3] - The social (S) dimension's impact on brand value is relatively weaker due to differences in standards between China and the West [2][3] ESG Practices and Corporate Governance - Leading companies typically adopt an embedded governance model for ESG, integrating it into strategic planning, product innovation, and supply chain management [2][3] - Hikvision has established a dual-axis governance structure, Huabao New Energy has developed a green factory system, BYD links ESG performance to executive compensation, and Haier Biomedical achieves a blend of commercial and social value through technological innovation [2][3] - These companies reflect a shift from "compliance-oriented" to "value-driven" ESG practices, aligning with international technical standards while retaining local characteristics [2][3] Challenges and Recommendations - Current challenges include non-unified ESG information disclosure standards, insufficient transformation capabilities of small and medium-sized enterprises, and the need for improved international discourse adaptability [3] - Recommendations include embedding ESG deeply into governance structures, constructing localized narrative systems, and enhancing industry chain collaboration [3] - The government should improve a tiered and categorized ESG standard system and establish diverse incentive mechanisms and public service platforms [3] Importance of ESG in Global Competitiveness - ESG has become a core indicator of corporate international competitiveness amid the global sustainable development agenda [3] - Chinese international enterprises need to implement systematic ESG practices to balance international standards with local adaptation, using environmental innovation as a breakthrough point to enhance brand value and international influence [3]

证券日报网讯2月3日，海尔生物在互动平台回答投资者提问时表示，截至2026年1月31日，公司股东总 数为14209户。 ...

Core Viewpoint - Kaos, the industrial internet platform under Haier Group, has officially submitted its application for listing on the Hong Kong Stock Exchange, aiming to become the ninth listed company in the Haier ecosystem, following a failed attempt to list on the A-share market [1][2]. Group 1: Company Overview - Kaos was established in April 2017 and has developed the COSMOPlat industrial internet platform, which ranks first in China's industrial data intelligent solutions market based on revenue in 2024 [2]. - The company has been preparing for its IPO for over five years, with a significant focus on industrial internet solutions while Haier Group concentrates on smart home businesses [2][5]. Group 2: Financial Performance - In 2023 and 2024, Kaos reported revenues of 4.994 billion yuan and 5.070 billion yuan, with net profits of -82.721 million yuan and 65.136 million yuan, respectively. For the first nine months of 2025, revenue reached 4.42 billion yuan with a net profit of 176 million yuan [3]. - The revenue from the IoT solutions segment was 3.14 billion yuan, a year-on-year increase of 10.86%, while the data intelligence solutions segment generated 1.28 billion yuan, up 59.64% year-on-year [3]. Group 3: Revenue Sources - Haier Group is the largest customer and supplier for Kaos, contributing 3.607 billion yuan, 3.421 billion yuan, and 2.549 billion yuan to Kaos's revenue in 2023, 2024, and the first nine months of 2025, respectively [3]. - Government subsidies have been a significant source of income for Kaos, amounting to 97.6 million yuan, 79.7 million yuan, and 50.5 million yuan in 2023, 2024, and the first nine months of 2025 [4]. Group 4: IPO Plans and Use of Proceeds - The funds raised from the IPO will primarily be used to enhance core platform capabilities, develop industrial models, expand market reach, and explore potential investment opportunities [5][6]. - The decision to shift from A-share to Hong Kong listing was influenced by regulatory uncertainties in the A-share market and the company's global expansion strategy [2][4].

在高级别圆桌对话环节，由道达尔集团亚洲副总裁、中国欧盟能源项目组主席徐忠华博士主持，国务院 原参事、跨境电商50人论坛主席汤敏先生，空中客车中国人力资源副总裁宁斐女士，科锐国际轮值CEO 曾诚女士，世界银行高级经济学家王德文先生，中金公司董事总经理赵可女士，美锦能源（氢能）董事 长姚锦丽女士等嘉宾，围绕"数字经济时代，产业如何系统性赋能青年人才可持续发展"展开深入交流， 从产业协同、金融支持、组织机制创新与人才培养模式升级等多个维度，系统探讨了青年在ESG支持企 业长期转型过程中的角色定位与发展路径。 来源：环球网 北京，2026年1月30日——企业未来的竞争力，取决于今天如何培养青年。在联合国2030年可持续发展 目标进入最后五年的冲刺阶段，2026"向善的力量"——ESG产业赋能全球青年可持续发展高级别圆桌会 议暨联合国全球领导力与ESG发展中心（UNGLEP）高级导师年会，于北京联想集团未来中心成功举 办。本次会议由联合国全球领导力与ESG发展中心（UNGLEP）与联想集团共同主办，汇聚来自联合国 系统、国际多边金融机构、全球领先跨国公司、新质生产力代表企业及顶尖学术智库的近百位代表，共 同回答一个时代 ...

资料显示，青岛海尔生物医疗股份有限公司位于山东省青岛市高新区丰源路280号海尔生物医疗新兴产 业园，成立日期2005年10月28日，上市日期2019年10月25日，公司主营业务涉及生物医疗低温存储设备 的研发、生产和销售。主营业务收入构成为：医疗器械及相关产品98.81%，安装收入0.74%，软件维护 服务收入0.42%，租赁收入0.02%。 截至1月20日，海尔生物股东户数1.40万，较上期增加5.33%；人均流通股22571股，较上期减少5.06%。 2025年1月-9月，海尔生物实现营业收入17.61亿元，同比减少1.17%；归母净利润1.98亿元，同比减少 35.83%。 2月2日，海尔生物跌3.42%，成交额1.13亿元。两融数据显示，当日海尔生物获融资买入额1721.44万 元，融资偿还2360.88万元，融资净买入-639.44万元。截至2月2日，海尔生物融资融券余额合计2.47亿 元。 融资方面，海尔生物当日融资买入1721.44万元。当前融资余额2.45亿元，占流通市值的2.41%，融资余 额超过近一年50%分位水平，处于较高位。 融券方面，海尔生物2月2日融券偿还2300.00股，融券卖出 ...